203 related articles for article (PubMed ID: 37443505)
1. The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia.
Lai CC; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Tu CY; Cheng WC; Chen CH
Medicine (Baltimore); 2023 Jul; 102(28):e34284. PubMed ID: 37443505
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
Huang CT; Chen CH; Chen WC; Wang YT; Lai CC; Fu PK; Kuo LK; Chen CM; Fang WF; Tu CY; Ku SC
Int J Antimicrob Agents; 2022 Jan; 59(1):106491. PubMed ID: 34871744
[TBL] [Abstract][Full Text] [Related]
3. Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.
Chen CH; Tu CY; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Lai CC
Infect Drug Resist; 2021; 14():2251-2258. PubMed ID: 34168466
[TBL] [Abstract][Full Text] [Related]
4. P1-6: Clinical effectiveness of cefoperazone-sulbactam versus piperacillin-tazobactam for the treatment of pneumonia in the elderly population.
Respirology; 2021 Nov; 26 Suppl 3():72. PubMed ID: 34799933
[No Abstract] [Full Text] [Related]
5. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
6. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: A single-centre study in Zhejiang Province, China.
Hua CZ; Wang HJ; Zhang Z; Tao XF; Li JP; Mi YM; Tang LF; Chen ZM
J Glob Antimicrob Resist; 2019 Sep; 18():47-51. PubMed ID: 30710647
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients.
Chen Y; Xiang Q; Liu L
J Int Med Res; 2021 May; 49(5):3000605211019661. PubMed ID: 34057835
[TBL] [Abstract][Full Text] [Related]
8. The effect of cefoperazone sulbactam and piperacillin tazobactam on mortality in Gram-negative nosocomial infections.
Guclu E; Kaya G; Ogutlu A; Karabay O
J Chemother; 2020 May; 32(3):118-123. PubMed ID: 32096456
[TBL] [Abstract][Full Text] [Related]
9. Cross-reactivity between piperacillin-tazobactam and cefoperazone-sulbactam in drug-induced immune thrombocytopenia.
He X; Huang W; Wan X; Li X; Chang Q; Ding L
J Int Med Res; 2023 Mar; 51(3):3000605231162434. PubMed ID: 36967671
[TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia.
Wang CY; Chen CH; Tu CY; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Lai CC
J Infect Public Health; 2022 Sep; 15(9):961-965. PubMed ID: 35930932
[TBL] [Abstract][Full Text] [Related]
11. Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases.
Sipahi OR; Arda B; Nazli-Zeka A; Pullukcu H; Tasbakan M; Yamazhan T; Ozkoren-Calik S; Sipahi H; Ulusoy S
Int J Clin Pract; 2014 Feb; 68(2):230-5. PubMed ID: 24372736
[TBL] [Abstract][Full Text] [Related]
12. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
[TBL] [Abstract][Full Text] [Related]
13. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia.
Aynioglu A; Mutlu B; Hacihanefioglu A
Rev Esp Quimioter; 2016 Apr; 29(2):69-75. PubMed ID: 26888338
[TBL] [Abstract][Full Text] [Related]
15.
Pragsam AK; Kumar DT; Doss CGP; Iyadurai R; Satyendra S; Rodrigues C; Joshi S; Roy I; Chaudhuri BN; Chitnis DS; Tapan D; Veeraraghavan B
Indian J Med Microbiol; 2018; 36(1):127-130. PubMed ID: 29735843
[TBL] [Abstract][Full Text] [Related]
16. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Wang H; Chen MJ;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
[TBL] [Abstract][Full Text] [Related]
17. Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study.
Tobudic S; Bahrs C; Schneider L; Paulussen E; Bartonickova L; Hagel S; Starzengruber P; Burgmann H; Pletz MW
Infection; 2023 Dec; 51(6):1749-1758. PubMed ID: 37462895
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.
Speich R; Imhof E; Vogt M; Grossenbacher M; Zimmerli W
Eur J Clin Microbiol Infect Dis; 1998 May; 17(5):313-7. PubMed ID: 9721959
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of antibiotic concentrations in drug dispensing in neonates: a laboratory-based study.
Zheng LY; Gu WP; Liang N; Gao LL; Guo WW; Li RR; Wang X; Hao GX; Van Den Anker J; Wu YE; Zhao W
BMJ Paediatr Open; 2023 Dec; 7(1):. PubMed ID: 38114241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
